1. Home
  2. GUTS vs MGX Comparison

GUTS vs MGX Comparison

Compare GUTS & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GUTS
  • MGX
  • Stock Information
  • Founded
  • GUTS 2010
  • MGX 2018
  • Country
  • GUTS United States
  • MGX United States
  • Employees
  • GUTS N/A
  • MGX N/A
  • Industry
  • GUTS
  • MGX
  • Sector
  • GUTS
  • MGX
  • Exchange
  • GUTS NYSE
  • MGX NYSE
  • Market Cap
  • GUTS 58.8M
  • MGX 62.1M
  • IPO Year
  • GUTS 2024
  • MGX 2024
  • Fundamental
  • Price
  • GUTS $1.58
  • MGX $1.52
  • Analyst Decision
  • GUTS Buy
  • MGX Strong Buy
  • Analyst Count
  • GUTS 1
  • MGX 4
  • Target Price
  • GUTS $10.00
  • MGX $13.00
  • AVG Volume (30 Days)
  • GUTS 930.5K
  • MGX 665.7K
  • Earning Date
  • GUTS 08-13-2025
  • MGX 08-13-2025
  • Dividend Yield
  • GUTS N/A
  • MGX N/A
  • EPS Growth
  • GUTS N/A
  • MGX N/A
  • EPS
  • GUTS N/A
  • MGX N/A
  • Revenue
  • GUTS $60,000.00
  • MGX $45,263,000.00
  • Revenue This Year
  • GUTS N/A
  • MGX N/A
  • Revenue Next Year
  • GUTS N/A
  • MGX $11.75
  • P/E Ratio
  • GUTS N/A
  • MGX N/A
  • Revenue Growth
  • GUTS N/A
  • MGX N/A
  • 52 Week Low
  • GUTS $0.87
  • MGX $1.23
  • 52 Week High
  • GUTS $4.92
  • MGX $5.50
  • Technical
  • Relative Strength Index (RSI)
  • GUTS 42.52
  • MGX 47.41
  • Support Level
  • GUTS $1.54
  • MGX $1.46
  • Resistance Level
  • GUTS $1.82
  • MGX $1.66
  • Average True Range (ATR)
  • GUTS 0.18
  • MGX 0.13
  • MACD
  • GUTS -0.07
  • MGX 0.00
  • Stochastic Oscillator
  • GUTS 5.06
  • MGX 46.30

About GUTS FRACTYL HEALTH INC

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Share on Social Networks: